CRL-2922 EA.hy926 人臍靜脈細胞融合細胞，ATCC 細胞|細胞系|細胞株|腫瘤細...

CRL-2922 EA.hy926 人臍靜脈細胞融合細胞，ATCC 細胞|細胞系|細胞株|腫瘤細胞|細胞；細胞庫管理規(guī)范，提供的細胞株背景清楚，提供參考文獻和優(yōu)培養(yǎng)條件！

ATCC® Number: CRL-2922™ Price:
Designations: EA.hy926
Depositors: CS Edgell
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: adherent
Organism: Homo sapiens (human)
Morphology: endothelial

Source: Tissue: somatic cell hybrid
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Restrictions: For-profit institutions must obtain license from University of North Carolina, Chapel Hill.
Antigen expression: Factor VIII-related antigen; Homo sapiens, expressed
DNA Profile (STR): Amelogenin: X
CSF1PO: 10,11,12
D13S317: 11
D16S539: 11,12
D5S818: 11
D7S820: 8,9,10
THO1: 6,8,9.3
TPOX: 8,9
vWA: 14,17
Comments: The human umbilical vein cell line, EA.hy926, was established by fusing primary human umbilical vein cells with a thioguanine-resistant clone of A549 by exposure to polyethylene glycol (PEG). Hybrid clones were selected in HAT medium and screened for factor VIII-related antigen. EA.hy926 cells have been maintained for more than 100 population doublings (PDLs). Electron photomicrographs demonstrate cytoplasmic distribution of Weibel-Palade bodies and tissue-specific organelles, characteristics of differentiated endothelial cell functions such as angiogenesis, homeostasis/thrombosis, blood pressure and inflammation. [PubMed: 6407019] [PubMed: 2079463]
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbeccos Modified Eagles Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10.
Atmosphere: air, 95; carbon dioxide (CO2), 5
Temperature: 37.0°C
Subculturing: Protocol: Volumes used in this protocol are for 75 sq cm flasks; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
1.Remove and discard culture medium.
2.Briefly rinse the cell layer with Ca++/Mg++ free Dulbeccos phosphate-buffered saline (D-PBS) or 0.25 (w/v) Trypsin - 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.
3.Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37C to facilitate dispersal.
4.Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
5.Transfer cell suspension to a centrifuge tube and spin at approximately 125 X g for 5 to 10 minutes. Discard supernatant.
6.Resuspend the cell pellet in fresh growth medium. Add appropriate aliquots of the cell suspension to new culture vessels. An inoculum of 2 X 10(3) to 3 X 10(3) viable cells/sq. cm is recommended.
7.Incubate cultures at 37C. Subculture when cell concentration reaches between 8 X 10(4) and 1 X 10(5) cells/sq. cm.
Interval: Twice a week
Subcultivation Ratio: A subcultivation ratio of 1:6 to 1:10 is recommended
Medium Renewal: Every 2 to 3 days

Preservation: Freeze medium: Complete Growth medium, 95; DMSO, 5
Storage temperature: liquid nitrogen vapor phase
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
0.25 (w/v) Trypsin - 0.53 mM EDTA in Hank BSS (w/o Ca++, Mg++):ATCC 30-2101
phosphate-buffered saline:ATCC 30-2200
Cell culture tested DMSO:ATCC 4-X
Erythrosin B vital stain solution:ATCC 30-2404
Trypan Blue vital stain solution:ATCC 30-2402
References: 92902: Edgell CJ, et al. Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc. Natl. Acad. Sci. USA 80: 3734-3737, 1983. PubMed: 6407019
92903: Bauer J, et al. In vitro model of angiogenesis using a human endothelium-derived permanent cell line: contributions of induced gene expression, G-proteins, and integrins. J. Cell. Physiol. 153: 437-449, 1992. PubMed: 1280276
92904: Edgell CJ, et al. Endothelium specific Weibel-Palade bodies in a continuous human cell line, EA.hy926. In Vitro Cell. Dev. Biol. 26: 1167-1172, 1990. PubMed: 2079463
92905: Rieber AJ, et al. Extent of differentiated gene expression in the human endothelium-derived EA.hy926 cell line. Thromb. Haemostasis 69: 476-480, 1993. PubMed: 8322270

 

如果您覺得“CRL-2922 EA.hy926 人臍靜脈細胞融合細胞”描述資料不夠齊全，請聯(lián)系我們獲取詳細資料。(聯(lián)系時請告訴我從給覽網(wǎng)看到的，我們將給您最大優(yōu)惠！)
本頁鏈接：http://m.521uz.com/com_xiangbio/sell/itemid-194763.html
已經(jīng)有7473位訪客查看了本頁.